

DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C.F., Armstrong, L.L., Goldman, M.P., dan Lance, L.L., 2009, *Drug Information Handbook*, 17th edition, Lexi-Comp for the American Pharmacist Association.
- Adiarto, S., 2012, *Rokok, Perokok Pasif, Kematian Kardiovaskular dan Jaminan Kesehatan*, Jurnal Kardiologi Indonesia, 33(3), 158-159.
- Ageno, W., Gallus, A.S., Wittkowsky, A., Crowthwr, M., Hylek, E.M., dan Palareti, G., 2012, *Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition*, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, CHEST Journal, 141: e44S–88S.
- Agustini, T.T., Arifin, H., dan Hanif, A.M., 2015, *Perbandingan Dosis Warfarin terhadap lama Tercapainya Target INR pada Pasien CHF dengan Fibrilasi Atrial*, Jurnal Sains Farmasi & Klinis: Sumatera Barat.
- Andersson, K., Melander, A., Svensson, C., Lind, O., dan Nilsson, J.L.G., 2005 *Repeat Prescriptions: Refill Adherence in Relation to Patient and Prescriber Characteristics, Reimbursement Level and Type of Medication*, The European Journal of Public Health Advance Access, 1-6.
- Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., dan Palareti, G., 2008, *Pharmacology and management of the vitamin k antagonists**: American college of chest physicians evidence-based clinical practice guidelines (8th edition). CHEST Journal, 133: 160S–198S.
- Arbring, K., Uppugunduri, S., dan Lindahl, T.L., 2013, *Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics*. BMC Health Services Research, 13: 85.
- Aronson, J.K., 2007, *Compliance, Concordance, Adherence*, British Journal of Clinical Pharmacology, 63(4), 383-384.
- Badan Pengawas Obat dan Makanan, 2015, *Antikoagulan Oral*, pionas.pom.go.id/ioni/bab-2-sistem-kardiovaskuler-0/26-antikoagulan-dan-protamin/261-antikoagulan-oral, 9 Juli 2021.
- Banerjee, C., Moon., Y.P., Paik., M.C., Rundek, T., Mora-McLaughlin, C., Vieira, J.R., Sacco, R.L., Elkind, M.S.V., 2010, *Duration of Diabetes and Risk of Ischemic Stroke The Northern Manhattan Study*, Aha Journal, 43:1212-1217.

- Cairns, D., 2004, *Intisari Kimia Farmasi*. Diterjemahkan oleh Puspita, M.R. pada tahun 2008. Ed 2, Jakarta, EGC.
- Camm, A.J., dkk., 2010, *Guidelines for The Management of Atrial Fibrillation*, European Heart Journal, 31, 2369-2469.
- Chakrabarti, S., 2014, *What's in a name? Compliance, adherence and concordance in chronic psychiatric disorders*, World Journal of Psychiatry, 4(2), 30-36.
- Dahlback, B., 2000, *Blood Coagulation*, The Lancet, 355(9215), 1627-1632.
- Devi, G.A.P.G.L., Aryabiantara, W., dan Hartawan, U., 2018, *Profil Penggunaan Antikoagulan pada Pasien Kardiovaskular yang Dirawat di Ruang ICCU RSUP Sanglah Periode Januari 2016-Juni 2016*, E-Jurnal Medika, 7(10).
- Deykin, D., 1970, *Warfarin Therapy*, The England Journal of Medicine.
- European Patients Forum, 2015, *Adherence and Concordance*, EPF Position Paper.
- Fang, M.C., Go, A.S., Hylek, E.M., Chang, Y., Henault, L.E., dan Jensvold, N.G., 2005, *Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study*. J Am Geriatr Soc. 2006;54:1231-6. [PMID: 16913990].
- Ghani, L., Susilawati, M.D., dan Novriani, H., 2016, *Faktor Risiko Dominan Penyakit Jantung Koroner di Indonesia*, Buletin Penelitian Kesehatan, 44(3), 153-164.
- Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., dan Singer, D.E., *Prevalence of Diagnosed Atrial Fibrillation in Adult*, JAMA, 285(18), 2370-2375.
- Greenblatt D.J. dan von Moltke L.L., 2005, *Interaction of Warfarin with Drugs, Natural substances, and Foods*, The Journal of Clinical Pharmacology, 45(2), 127-132.
- Hapsari, D.C., Suwaldi, dan Kusharwanti, W., 2014, *Efektifitas dan Keamanan Antikoagulan pada Sindroma Koroner Akut Tanpa Elevasi Segmen ST*, Jurnal Manemen dan Pelayanan Farmasi, 4(2), 111-116.
- Hart, R.G., Pearce, L.A., dan Agullar, M.I., 2007, *Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation*, American Chollege of Physicians, Ann Intern Med. 2007;146:857-867.
- Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, s., Izumi, T., Koretsune, Y., Kajikawa, M., Kato, M., Ueda, H., Iwamoto, K.,

- dan Tajiri, M., 2012, *Rivaroxaban vs. Warfarin in Japanese Patients with Atrial Fibrillation*, *Circulation Journal*. 76: 2104-2111.
- Hylek, E.M., Skates, S.J., dan Sheehan, M.A., dan Singer, D.E., 1996, *An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation*. *N Engl J Med*, 1996; 335:540-546.
- Janes, S., Challis, R., dan Fisher, F., 2004, *Safe introduction of warfarin for thrombotic prophylaxis in atrial fibrillation requiring only a weekly INR*. *Clinical and Laboratory Haematology*, 26: 43-47.
- Kearon, C., Ginsberg, J.S., Kovacs, M.J., Anderson, D.R., Wells, P., Julian J.A., MacKinnon, B., Weitz, J.I., Crowther, M.A., Demers, C., Kahn, S.R., Kassis, J., Rodger, M., Hambleton, J., dan Gent, M., *A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism*, *N Engl J Med*, 340:901-907.
- Kementerian Kesehatan RI, 2014, *Infodatin Pusat Data dan Informasi Situasi Kesehatan Jantung*, Jakarta.
- Killey, M., 2005, *Limits on Patient Responsibility*, *J Med Philos*, 30:189-206.
- Kimmel, S.E., Chen, Z., Price, M., Parker, C.S., Metlay, J.P., Christie, J.D., Brensinger, C.M., Newcomb, C.W., Samaha, F.F., dan Gross, R., 2007, *The Influence of Patient Adherence on Anticoagulation Control With Warfarin*, American Medical Association, *Arch Intern Med*, 167:229-235.
- Kleinsinger, F., 2018, *The Unmet Challenge of Medication Nonadherence*, *Perm J* 2018, 22: 18-033.
- Kusumawaty, J., Hidayat, N., dan Ginanjar, E., 2016, *Hubungan Jenis Kelamin dengan Intensitas Hipertensi pada Lansia di Wilayah Kerja Puskesmas Lakbok Kabupaten Ciamis*, *Mutiara Medika*, 16(2), 46-51.
- Laurence, L.B., Keith, L.P., dan Donald, K.B., 2008, *Goodman and Gilman's Manual of Pharmacology and Therapeutics*, Mc Grawhill Medical Pub 11, 544 cit Alamsyah, A.S., Ulfa, N.M., Sugiarto, L., *Profil Penggunaan Loop Diuretik (Furosemid) pada Pasien PGK dengan Hemodialisis di Rumah Sakit X Surabaya*.
- Lemeshow, S., Hosmer Jr, D.W., Klar, J., dan Lwanga, S.K., 1990, *Adequacy Of Sample Size In Health Studies*. New York: World Health Organization.

- Levine, M.N., Raskob, G., Landefeld, S., dan Kearon, C., 2001, *Hemorrhagic complications of anticoagulant treatment*. CHEST Journal, 119: 108S–121S.
- Lloyd-Jones, D.M., Hong, Y., Labarthe, D., Mozaffarin, D., Appel, L.J., Horn, L.V., Greenlund, K., Daniels, S., Nichol, G., Tomaselli, G.F., Arnett, D.K., Fonarow, G.C., Ho, P.M., Lauer, M.S., Masoudi, F.A., Robertson, R.M., Roger, V., Schwamm, L.H., Sorlie, P., Yancy, C.W., Rosamond, W.D., 2010, *Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond*, Circulation, 121(4), 586-613.
- Megawati, S., Lestari, T., dan Setyani, W.L., 2019. *Evaluasi Penggunaan Warfarin Oral terhadap Nilai INR Pasien Jantung Rawat Jalan RSUD Kabupaten Tangerang 2018*, Jurnal Farmagazine, Vol. VI No. 2, 10-17.
- Michael, dan Ramadhania, Z.M., 2017, *Penginduksi Perdarahan*, Farmaka, 15(4), 288-292 cit. Apriyandi, R.A., Puspitasari, I.M., Putriana, N.A., Efek Samping Penggunaan Warfarin dan Kombinasi Warfarin dengan Obat Lain, *Farmaka*, 18(2),132-140.
- Mursiany, A., Ernawati, N., dan Oktaviani, N., 2015, *Gambaran Penggunaan Obat dan Kepatuhan Mengonsumsi Obat pada Penyakit Hipertensi di Instalasi Rawat Jalan RSUD Kraton Kabupaten Pekalongan Tahun 2013*, Pena Jurnal Ilmu Pengetahuan dan Teknologi, 28(2), 237-248.
- Ponikowski, P., Voors, A.A., dan Anker, S.D., 2016, *2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure*, uropan Journal f HeartFailure, 18, 891-975.
- Pratiwi F., I., Rifqi, S., dan Maharani, N., 2011, *Komplikasi pada Pasien Infark Miokard Akut ST-Elevasi (STEMI) yang Mendapat maupun Tidak Mendapat Terapi Reperfusi*, RSUP Dr. Kariadi Semarang.
- Pusmarani, J., Mustofa, dan Darmawan, E., 2015, *Pengaruh Pemberian Edukasi Obat terhadap Kepatuhan Minum Obat Warfarin pada Pasien Sindrom Koroner Akut dan Fibrilasi Atrium di Rumah Sakit PKU Muhammadiyah Yogyakarta*, Jurnal Farmasi Klinik Indonesia, 4(4), 257-258.
- Rahmawati, D.U. dan Mutmainah, N., 2021, *Kajian Interaksi Obat Potensial pada Pasien Penyakit Jantung Koroner Rawat Inap di RSUD Moewardi Tahun 2018*, University Research Clloquium, 417-428.

- Rowland, M. dan Tozer, T.N., 2011, *Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications*, 4th ed. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia.
- Sarwar, N., Gao, P. Seshasai, SR.K., dan Gobin, R., 2010, *Diabetes Mellitus, Fasting Blood Glukose Concentration, and Risk of Vascular Disease: A Collaborative Meta-analysis of 102 Prospective Studies*, *Lancet*, 375(9733), 2215-2222.
- Sikka, P. dan Bindra, V.K., 2010, *Newer Antithrombotic Drugs*, *Indian Journal of Critical Care Medicine*, Vol 14 Issue 4.
- Simpson, S.H., Eurich, D.T., Majumdar, S.R., Padwal, R.S., Tsuyuki, R.T., Varney, J., Johnson, J.A., 2006, *Meta -analysis of the Association between Adherence to Drug Theraphy and Mortality*, *BMJ*, 333: 15-20.
- Schulman, S., Kearon, C. Kakkar, A.K., Mismetti, P., Schellong, S., dan Eriksson, H., 2009, *Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism*, *N Engl J Med*, 361: 2342-52.
- Sun, S., Wang, M., Su, L., Li, J., Li, H., dan Gu, D., 2006, *Study on warfarin plasma concentration and its correlation with international normalized ratio*. *Journal of Pharmaceutical and Biomedical Analysis*, 42: 218–222.
- The EINSTEIN Investigators, 2009, *Oral Rivaioxaban for Symptomatic Venous Thromboembolism*, *N Engl J Med*, 363: 2499-510.
- Thowfighi, A., Zheng, L., dan Ovibiagele, B., 2009, *Sex-specific Trends in Midlife Coronary Heart Disease Risk and Prevalence*, *Arch Intern Med.*, 169(19), 1762-1766.
- Touchette, D.R., Mcguinness, M.E., Stoner, S., Shute, D., Edwards, J.M., dan Ketchum, K., 2008, *Improving outpatient warfarin use for hospitalized patients with atrial fibrillation*. *Pharmacy Practice*, 6(1), 43-50.
- World Health Organization, 2003, *Adherence to Long-term Therapies*, WHO Library Cataloguing.
- Woodwell, D.A. dan Cherry, D.K., 2004, *National Ambulatory Medical Care Survey: 2002 summary*. *Adv Data*, (346):1-44.
- Zehnder, J.L., 2009, *Drugs Used In Disorders of Coagulation*, dalam: Katzung, B.G. (Ed.), *Basic and Clinical Pharmacology*, 11th Edition. McGraw Hill Professional, Amerika, hal. 257–296.